Musculoskeletal Pain Market Insights, Epidemiology and Market Forecast-2028

Musculoskeletal Pain Market Insights, Epidemiology and Market Forecast-2028

  • Pages: 171
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Mar, 2019
  • SKU: DIMI0437
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Gobal License
    ()
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Musculoskeletal Pain Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the Musculoskeletal Pain market trends in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.
The Musculoskeletal Pain Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Musculoskeletal Pain market size from 2017 to 2028 segmented by seven major markets. The Musculoskeletal Pain Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the Musculoskeletal Pain market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Musculoskeletal Pain - Disease understanding
Generally, pain is the foremost complaint of patients with problems of the back, thus making pain evaluation a fundamental requisite in the outcome assessment in spinal surgery. Pain intensity, pain-related disability, pain duration and pain effect are the aspects that define pain and its effects. Musculoskeletal pain affects the bones, muscles, ligaments, tendons, and nerves. It can be acute (having a rapid onset with severe symptoms) or chronic (long-lasting). Musculoskeletal pain can be localized in one area, or widespread. Lower back pain is the most common type of musculoskeletal pain. Other common types include tendonitis, myalgia (muscle pain), and stress fractures. Acute and chronic pain is influenced by and interacts with physical, emotional, psychological, and social factors, and a biopsychosocial framework is increasingly applied in clinical practice.
Musculoskeletal pain has a large socio-economical impact with only a few available proficient pain management strategies. Musculoskeletal pain often progresses over time resulting in more hyperalgesia and larger pain areas. Peripheral and spreading sensitizations are important mechanisms for the translation of acute local pain to chronic musculoskeletal pain conditions. Several mechanisms, such as sensitizations, descending control, central integration and expansion of receptive fields/referred pain have been identified in musculoskeletal nociception and pain.
The DelveInsight Musculoskeletal Pain market report gives a thorough understanding of the Musculoskeletal Pain by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Musculoskeletal Pain in the US, Europe, and Japan.

Musculoskeletal Pain Epidemiology
The Musculoskeletal Pain epidemiology division provides insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by diagnosed prevalent population, type-specific prevalent population, gender-specific prevalent population and site-specific Musculoskeletal Pain prevalent population.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the Musculoskeletal Pain prevalent population was estimated to be 254,045,592 [7MM] in 2018. United States accounts for the highest Musculoskeletal Pain cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries, the UK had the highest prevalent patient population of Musculoskeletal Pain, followed by Italy. The United States accounted for the maximum number of musculoskeletal pain patients with 138,684,042 cases in 2018. In terms of sex-specific, most of the patients have been diagnosed with Musculoskeletal Pain were females. The prevalence of musculoskeletal pain is estimated for six anatomical areas: neck area; shoulder area (including neck, shoulder, and higher back); elbow, wrist, and hand area (including upper arm, elbow, lower arm, wrist, hand, and finger); lower back area (including lower back); hip and knee area (including hip, femur, and knee), and ankle and foot area (including crus, ankle, and foot).

Musculoskeletal Pain Management
Musculoskeletal pain (MSP) is the most common cause of disability globally and is frequently managed in primary care. Pain as a result of musculoskeletal problems of the back, neck, shoulder, knee and multi-site pain is an increasing cause of diminished quality of life and increased demand on healthcare.
Currently, musculoskeletal pain is managed by a plethora of treatment options. These include non-pharmacological treatments (e.g. self-management advice and education, exercise therapy, manual therapy and psychosocial interventions), complementary therapies (acupuncture) and pharmacological interventions (analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections. In patients with refractory symptoms, surgical interventions, e.g. arthroscopic debridement, total knee replacements, and laminectomies) may be considered. However, the existing therapies are useful for treating the symptoms of the disease, but are not disease-modifying and thus do not address the underlying disease cause. As a result, it is believed that the most significant unmet need is a therapy that can not only improve the patient’s pain and function but has the ability to reverse, halt or slow disease progression.
Musculoskeletal Pain Market Outlook
The Musculoskeletal Pain market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The primary unmet need for Musculoskeletal Pain treatment market is the dearth of approved novel therapies. To meet the increasing demand for the treatment of Musculoskeletal Pain, companies have shifted their focus towards the development of various novel therapies with less adverse events as compared to already available analgesics and NSAIDs.
According to DelveInsight, the global market of Musculoskeletal Pain (MSP) was estimated to be USD 3,792.6 million in 2018. The United States accounts for the largest Musculoskeletal Pain market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The Musculoskeletal Pain market size in the United States was found to be USD 2450.02 million in 2018.  Among the EU5 countries, the UK had the highest market size with 266.0 Million in 2018, while France had the lowest Musculoskeletal Pain market size. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the Musculoskeletal Pain market size during the forecasted period of 2019-2028.
Musculoskeletal Pain Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
In order to meet the high unmet need of Musculoskeletal Pain treatment regimen, companies across the globe have shifted their focus towards this therapeutic area. Thus, various experimental studies are undergoing to find promising therapies. Companies such as Pfizer/Elli Lilly and company, Mesoblast, Mitsubishi Tanabe Pharma, Regeneron Pharmaceuticals, Ampio Pharmaceuticals, Charleston Laboratories, Nektar Therapeutics, Centrexion Therapeutics, MDM S.p.A., Braeburn Pharmaceuticals, and Egalet Ltd are involved in developing therapies for the Musculoskeletal Pain treatment. Therapies such as NKTR-181 (Nektar Therapeutics), Egalet-002 (Egalet Ltd), Tizaspray (MDM S.p.A), Ampion (Ampio Pharmaceuticals), CAM2038 (Braeburn Pharmaceuticals), CNTX-4975 (Centrexion Therapeutics), Fasinumab (REGN475) (Regeneron Pharmaceuticals), Tanezumab (Pfizer/Eli Lilly and Company), Rexlemestrocel-L (Mesoblast) etc. are under-development for the Musculoskeletal Pain treatment.
Out of these emerging therapies, Egalet and Tizaspray are expected to reach first in the market by 2019, yet the largest market share is going to be captured by Rexlemestrocel-L (since it is a cell replacement therapy), followed by monoclonal antibodies, Fasinumab and Tanezumab, while Tizaspray is expected to capture the lowest Musculoskeletal Pain market share of all the therapies.

Musculoskeletal Pain Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Musculoskeletal Pain Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Musculoskeletal Pain Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Musculoskeletal Pain market.
  • Organize sales and marketing efforts by identifying the best opportunities for Musculoskeletal Pain market.
  • To understand the future market competition in the Musculoskeletal Pain market.

 

1 Key Insights
2 Musculoskeletal Pain Market Overview at a Glance
2.1 Total Market Share (%) Distribution of Musculoskeletal Pain in 2016
2.2 Total Market Share (%) Distribution of Musculoskeletal Pain in 2027
3 Musculoskeletal Pain Disease Background and Overview
3.1 Introduction
3.2 General Aspects of Pain
3.3 Musculoskeletal Pain Types
3.4 Musculoskeletal Pain Symptoms
3.5 Musculoskeletal Pain Causes
3.6 Basic Aspects of Musculoskeletal Pain
3.7 Central Mechanisms in Musculoskeletal Pain
3.8 Musculoskeletal Pain Pathophysiology
3.9 Musculoskeletal Pain Diagnosis
3.1 Musculoskeletal Pain Biomarkers
3.11 Instruments to measure pain affect
4 Musculoskeletal Pain Epidemiology and Patient Population
4.1 Key Findings
5 Musculoskeletal Pain Total Prevalent Population in 7MM
6 United States
6.1 Assumptions and Rationale
6.2 Total Prevalent Population of Musculoskeletal Pain in the United States
6.3 Gender – Specific Prevalent Population of Musculoskeletal Pain in the United States
6.4 Type – Specific Prevalent Population of Musculoskeletal Pain in the United States
6.5 Site – Specific Prevalent Population of Musculoskeletal Pain in the United States
7 EU5
7.1 Assumptions and Rationale
7.2 Germany
7.2.1 Total Prevalent Population of Musculoskeletal Pain in Germany
7.2.2 Gender – Specific Prevalent Population of Musculoskeletal Pain in Germany
7.2.3 Type – Specific Prevalent Population of Musculoskeletal Pain in Germany
7.2.4 Site – Specific Prevalent Population of Musculoskeletal Pain in Germany
7.3 France
7.3.1 Total Prevalent Population of Musculoskeletal Pain in France
7.3.2 Gender – Specific Prevalent Population of Musculoskeletal Pain in France
7.3.3 Type – Specific Prevalent Population of Musculoskeletal Pain in France
7.3.4 Site – Specific Prevalent Population of Musculoskeletal Pain in France
7.4 Italy
7.4.1 Total Prevalent Population of Musculoskeletal Pain in Italy
7.4.2 Gender – Specific Prevalent Population of Musculoskeletal Pain in Italy
7.4.3 Type – Specific Prevalent Population of Musculoskeletal Pain in Italy
7.4.4 Site – Specific Prevalent Population of Musculoskeletal Pain in Italy
7.5 Spain
7.5.1 Total Prevalent Population of Musculoskeletal Pain in Spain
7.5.2 Gender – Specific Prevalent Population of Musculoskeletal Pain in Spain
7.5.3 Type – Specific Prevalent Population of Musculoskeletal Pain in Spain
7.5.4 Site – Specific Prevalent Population of Musculoskeletal Pain in Spain
7.6 United Kingdom
7.6.1 Total Prevalent Population of Musculoskeletal Pain in the United Kingdom
7.6.2 Gender – Specific Prevalent Population of Musculoskeletal Pain in the United Kingdom
7.6.3 Type – Specific Prevalent Population of Musculoskeletal Pain in the United Kingdom
7.6.4 Site – Specific Prevalent Population of Musculoskeletal Pain in the United Kingdom
7.7 Japan
7.7.1 Assumptions and Rationale
7.7.2 Total Prevalent Population of Musculoskeletal Pain in the Japan
7.7.3 Gender – Specific Prevalent Population of Musculoskeletal Pain in the Japan
7.7.4 Type – Specific Prevalent Population of Musculoskeletal Pain in the Japan
7.7.5 Site – Specific Prevalent Population of Musculoskeletal Pain in Japan
8 Musculoskeletal Pain Treatment in the emergency department
8.1 Chronic Musculoskeletal Pain in older adults
8.2 Chronic Musculoskeletal Pain Treatment Algorithm
9 Unmet Needs
10 Musculoskeletal Pain Emerging Therapies
10.1 Key Cross Competition
10.2 NKTR-181: Nektar Therapeutics
10.2.1 Drug Description
10.2.2 Other Developmental Activities
10.2.3 Clinical Development
10.2.4 Safety and Efficacy
10.2.5 Product Profile
10.3 Ampion: Ampio Pharmaceuticals
10.3.1 Product Description
10.3.2 Other Developmental Activities
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.4 Tanezumab: Eli Lilly/Pfizer
10.4.1 Product Description
10.4.2 Other Developmental Activities
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
10.5 Fasinumab: Regeneron Pharmaceuticals
10.5.1 Product Description
10.5.2 Other Developmental Activities
10.5.3 Clinical Development
10.5.4 Safety and Efficacy
10.5.5 Product Profile
10.6 CNTX-4975:  Centrexion Therapeutics
10.6.1 Drug Description
10.6.2 Other Developmental Activities
10.6.3 Clinical Development
10.6.4 Safety and Efficacy
10.6.5 Product Profile
10.7 MPC-06-ID (Rexlemestrocel-L): Mesoblast
10.7.1 Drug Description
10.7.2 Other Developmental Activities
10.7.3 Clinical Development
10.7.4 Safety and Efficacy
10.7.5 Product Profile
10.8 Tizaspray: MDM S.p.A
10.8.1 Drug Description
10.8.2 Clinical Development
10.8.3 Safety and Efficacy
10.8.4 Product Profile
10.9 CAM2038: Braeburn Pharmaceuticals
10.9.1 Drug Description
10.9.2 Other Developmental Activities
10.9.3 Clinical Development
10.9.4 Product Profile
10.1 Egalet-002: Egalet Corporation
10.10.1 Drug Description
10.10.2 Other Developmental Activities
10.10.3 Clinical Development
10.10.4 Safety and Efficacy
10.10.5 Product Profile
11 Musculoskeletal Pain Market Analysis 7MM
11.1 Key Findings
11.1 Musculoskeletal Pain Market Size in 7MM
12 United States: Market Outlook
12.1 United States Market Size
12.1.1 Musculoskeletal Pain Total Market size in the US
12.1.2 Musculoskeletal Pain Market Size by Therapies in the US
13 EU-5 countries: Market Outlook
13.1 Germany Market Size
13.1.1 Musculoskeletal Pain Total Market size
13.1.2 Musculoskeletal Pain Market Size by Therapies in Germany
13.2 France Market Size
13.2.1 Musculoskeletal Pain Total Market size
13.2.2 Musculoskeletal Pain Market Size by Therapies in France
13.3 Italy Market Size
13.3.1 Musculoskeletal Pain Total Market size
13.3.2 Musculoskeletal Pain Market Size by Therapies in Italy
13.4 Spain Market Size
13.4.1 Musculoskeletal Pain Total Market size
13.4.2 Musculoskeletal Pain Market Size by Therapies in Spain
13.5 United Kingdom Market Size
13.5.1 Musculoskeletal Pain Total Market size
13.5.2 Musculoskeletal Pain Market Size by Therapies in the UK
14 Japan Market Outlook
14.1 Japan Market Size
14.1.1 Musculoskeletal Pain Total Market size
14.1.2 Musculoskeletal Pain Market Size by Therapies in Japan
15 Market Drivers
16 Market Barriers
17 Appendix
17.1 Musculoskeletal Pain Report Methodology
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Figure 3: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Figure 4: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 5: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 6: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Figure 7: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Figure 8: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 9: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 10: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Figure 11: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Figure 12: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 13: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 14: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Figure 15: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Figure 16: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 17: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 18: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Figure 19: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Figure 20: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 21: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 22: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Figure 23: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Figure 24: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 25: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 26: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Figure 27: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Figure 28: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 29: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Figure 30: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Figure 31: World Health Organization analgesic ladder
Figure 32: Treatment Algorithm for Chronic Musculoskeletal Pain
Figure 33: Unmet Needs of Musculoskeletal Pain
Figure 34: Market Size of Musculoskeletal Pain in the 7MM in USD Million (2016-2027)
Figure 35: Market Size of Musculoskeletal Pain in the US, USD Millions (2016-2027)
Figure 36: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Figure 37: Market Size of Musculoskeletal Pain in Germany, USD Millions (2016-2027)
Figure 38: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Figure 39: Market Size of Musculoskeletal Pain in France, USD Millions (2016-2027)
Figure 40: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Figure 41: Market Size of Musculoskeletal Pain in Italy, USD Millions (2016-2027)
Figure 42: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Figure 43: Market Size of Musculoskeletal Pain in Spain, USD Millions (2016-2027)
Figure 44: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Figure 45: Market Size of Musculoskeletal Pain in the UK, USD Millions (2016-2027)
Figure 46: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Figure 47: Market Size of Musculoskeletal Pain in Japan, USD Millions (2016-2027)
Figure 48: Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)
Figure 49: Market Drivers of Musculoskeletal Pain
Figure 50:Market Barriers of Musculoskeletal Pain

Table 1: Total Prevalent Population of Musculoskeletal Pain in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Musculoskeletal Pain in the US (2016-2027)
Table 3: Gender Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 4: Type Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 5: Site-Specific Prevalence of Musculoskeletal Pain in the US (2016-2027)
Table 6: Total Prevalent Population of Musculoskeletal Pain in Germany (2016-2027)
Table 7: Gender Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 8: Type Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 9: Site-Specific Prevalence of Musculoskeletal Pain in Germany (2016-2027)
Table 10: Total Prevalent Population of Musculoskeletal Pain in France (2016-2027)
Table 11: Gender Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 12: Type Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 13: Site-Specific Prevalence of Musculoskeletal Pain in France (2016-2027)
Table 14: Total Prevalent Population of Musculoskeletal Pain in Italy (2016-2027)
Table 15: Gender Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 16: Type Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 17: Site-Specific Prevalence of Musculoskeletal Pain in Italy (2016-2027)
Table 18: Total Prevalent Population of Musculoskeletal Pain in Spain (2016-2027)
Table 19: Gender Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 20: Type Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 21: Site-Specific Prevalence of Musculoskeletal Pain in Spain (2016-2027)
Table 22: Total Prevalent Population of Musculoskeletal Pain in the UK (2016-2027)
Table 23: Gender Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 24: Type Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 25: Site-Specific Prevalence of Musculoskeletal Pain in the UK (2016-2027)
Table 26: Total Prevalent Population of Musculoskeletal Pain in Japan (2016-2027)
Table 27: Gender Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 28: Type Specific Prevalence of Musculoskeletal Pain in the Japan (2016-2027)
Table 29: Site-Specific Prevalence of Musculoskeletal Pain in Japan (2016-2027)
Table 30: Emerging Drugs Analysis
Table 31: NKTR-181, Clinical Trial Description, 2019
Table 32: Ampion, Clinical Trial Description, 2019
Table 33: Tanezumab, Clinical Trial Description, 2019
Table 34: Fasinumab, Clinical Trial Description, 2019
Table 35: CNTX-4975, Clinical Trial Description, 2019
Table 36: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 37: Tizaspray, Clinical Trial Description, 2019
Table 38: CAM2038, Clinical Trial Description, 2019
Table 39: Egalet-002, Clinical Trial Description, 2019
Table 40:  Market Size of Musculoskeletal Pain in 7MM in USD Million (2016-2027)
Table 41: The US Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 42: Market Size of Musculoskeletal Pain by therapies in the US, in USD Million (2016-2027)
Table 43: Germany Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 44: Market Size of Musculoskeletal Pain by therapies in Germany, in USD Million (2016-2027)
Table 45:  France Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 46: Market Size of Musculoskeletal Pain by therapies in France, in USD Million (2016-2027)
Table 47:  Italy Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 48: Market Size of Musculoskeletal Pain by therapies in Italy, in USD Million (2016-2027)
Table 49: Spain Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 50: Market Size of Musculoskeletal Pain by therapies in Spain, in USD Million (2016-2027)
Table 51: The UK Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 52: Market Size of Musculoskeletal Pain by therapies in the UK, in USD Million (2016-2027)
Table 53: Japan Market Size of Musculoskeletal Pain in USD Million (2016-2027)
Table 54:Market Size of Musculoskeletal Pain by therapies in Japan, in USD Million (2016-2027)

Figure 1: Pain Intensity Assessment Scales
Figure 2: Total Prevalent Populatio